ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Treating Chronic Myeloid Leukemia by Phase Market Research Report 2024
Published Date: October 2024
|
Report Code: QYRE-Auto-16I18356
Home | Market Reports | Health| Health Conditions| Cancer
Global Treating Chronic Myeloid Leukemia by Phase Market Research Report 2024
BUY CHAPTERS

Global Treating Chronic Myeloid Leukemia by Phase Market Research Report 2024

Code: QYRE-Auto-16I18356
Report
October 2024
Pages:97
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novartis
Bristol–Myers Squibb
Pfizer Inc
Hansoh Pharmaceutical
Takeda Pharmaceuticals
Sun Pharmaceuticals
Mylan NV
Dr. Reddy’s Laboratories
TEVA
Eugia Pharma
Hetero
Sawai Pharmaceutical
Lupin Ltd
Apotex
Chia Tai-Tianqing Pharmaceutical
Qilu Pharmaceutical
CSPC Ouyi Pharmaceutical
Suzhou Thery Pharmaceutical
Lunan Pharmaceutical

Treating Chronic Myeloid Leukemia by Phase Market

The treatment of chronic myeloid leukemia (CML) is structured around the disease's phases: chronic, accelerated, and blast. In the chronic phase, first-line therapy typically involves tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, or nilotinib. If CML progresses to the accelerated phase, treatment may shift to a different TKI, combination therapies, or clinical trials to manage resistance. In the blast phase, characterized by acute leukemia-like features, more intensive treatments such as chemotherapy or stem cell transplantation are often required.
The global Treating Chronic Myeloid Leukemia by Phase market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Treating Chronic Myeloid Leukemia by Phase is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Treating Chronic Myeloid Leukemia by Phase is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Treating Chronic Myeloid Leukemia by Phase in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Treating Chronic Myeloid Leukemia by Phase include Novartis, Bristol Myers Squibb, Pfizer, Hansoh Pharmaceutical, Takeda Pharmaceuticals, Sun Pharmaceuticals, Mylan, Dr. Reddy's Laboratories, Teva, Eugia Pharma, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Treating Chronic Myeloid Leukemia by Phase, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Treating Chronic Myeloid Leukemia by Phase.
The Treating Chronic Myeloid Leukemia by Phase market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Treating Chronic Myeloid Leukemia by Phase market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Treating Chronic Myeloid Leukemia by Phase companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Treating Chronic Myeloid Leukemia by Phase Market Report

Report Metric Details
Report Name Treating Chronic Myeloid Leukemia by Phase Market
Segment by Type
  • Chronic Phase
  • Accelerated Phase
  • Blast Phase
Segment by Application
  • Hospitals
  • Clinics
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Novartis, Bristol Myers Squibb, Pfizer, Hansoh Pharmaceutical, Takeda Pharmaceuticals, Sun Pharmaceuticals, Mylan, Dr. Reddy's Laboratories, Teva, Eugia Pharma, Hetero, Sawai Pharmaceutical, Lupin, Apotex, Chia Tai Tianqing Pharmaceutical, Qilu Pharmaceutical, CSPC Ouyi Pharmaceutical, Suzhou Thery Pharmaceutical, Lunan Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Treating Chronic Myeloid Leukemia by Phase company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Treating Chronic Myeloid Leukemia by Phase Market report?

Ans: The main players in the Treating Chronic Myeloid Leukemia by Phase Market are Novartis, Bristol Myers Squibb, Pfizer, Hansoh Pharmaceutical, Takeda Pharmaceuticals, Sun Pharmaceuticals, Mylan, Dr. Reddy's Laboratories, Teva, Eugia Pharma, Hetero, Sawai Pharmaceutical, Lupin, Apotex, Chia Tai Tianqing Pharmaceutical, Qilu Pharmaceutical, CSPC Ouyi Pharmaceutical, Suzhou Thery Pharmaceutical, Lunan Pharmaceutical

What are the Application segmentation covered in the Treating Chronic Myeloid Leukemia by Phase Market report?

Ans: The Applications covered in the Treating Chronic Myeloid Leukemia by Phase Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the Treating Chronic Myeloid Leukemia by Phase Market report?

Ans: The Types covered in the Treating Chronic Myeloid Leukemia by Phase Market report are Chronic Phase, Accelerated Phase, Blast Phase

Recommended Reports

Leukemia Therapeutics

Advanced Cancer Drugs

Cell & Immunotherapies

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Treating Chronic Myeloid Leukemia by Phase Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Chronic Phase
1.2.3 Accelerated Phase
1.2.4 Blast Phase
1.3 Market by Application
1.3.1 Global Treating Chronic Myeloid Leukemia by Phase Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Treating Chronic Myeloid Leukemia by Phase Market Perspective (2019-2030)
2.2 Global Treating Chronic Myeloid Leukemia by Phase Growth Trends by Region
2.2.1 Global Treating Chronic Myeloid Leukemia by Phase Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Treating Chronic Myeloid Leukemia by Phase Historic Market Size by Region (2019-2024)
2.2.3 Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Region (2025-2030)
2.3 Treating Chronic Myeloid Leukemia by Phase Market Dynamics
2.3.1 Treating Chronic Myeloid Leukemia by Phase Industry Trends
2.3.2 Treating Chronic Myeloid Leukemia by Phase Market Drivers
2.3.3 Treating Chronic Myeloid Leukemia by Phase Market Challenges
2.3.4 Treating Chronic Myeloid Leukemia by Phase Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Treating Chronic Myeloid Leukemia by Phase Players by Revenue
3.1.1 Global Top Treating Chronic Myeloid Leukemia by Phase Players by Revenue (2019-2024)
3.1.2 Global Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Players (2019-2024)
3.2 Global Treating Chronic Myeloid Leukemia by Phase Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Treating Chronic Myeloid Leukemia by Phase Revenue
3.4 Global Treating Chronic Myeloid Leukemia by Phase Market Concentration Ratio
3.4.1 Global Treating Chronic Myeloid Leukemia by Phase Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Treating Chronic Myeloid Leukemia by Phase Revenue in 2023
3.5 Global Key Players of Treating Chronic Myeloid Leukemia by Phase Head office and Area Served
3.6 Global Key Players of Treating Chronic Myeloid Leukemia by Phase, Product and Application
3.7 Global Key Players of Treating Chronic Myeloid Leukemia by Phase, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Treating Chronic Myeloid Leukemia by Phase Breakdown Data by Type
4.1 Global Treating Chronic Myeloid Leukemia by Phase Historic Market Size by Type (2019-2024)
4.2 Global Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Type (2025-2030)
5 Treating Chronic Myeloid Leukemia by Phase Breakdown Data by Application
5.1 Global Treating Chronic Myeloid Leukemia by Phase Historic Market Size by Application (2019-2024)
5.2 Global Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Treating Chronic Myeloid Leukemia by Phase Market Size (2019-2030)
6.2 North America Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2019-2024)
6.4 North America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Treating Chronic Myeloid Leukemia by Phase Market Size (2019-2030)
7.2 Europe Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2019-2024)
7.4 Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size (2019-2030)
8.2 Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size by Region (2019-2024)
8.4 Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Treating Chronic Myeloid Leukemia by Phase Market Size (2019-2030)
9.2 Latin America Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2019-2024)
9.4 Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Size (2019-2030)
10.2 Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2019-2024)
10.4 Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Treating Chronic Myeloid Leukemia by Phase Introduction
11.1.4 Novartis Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
11.1.5 Novartis Recent Development
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Company Details
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb Treating Chronic Myeloid Leukemia by Phase Introduction
11.2.4 Bristol Myers Squibb Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
11.2.5 Bristol Myers Squibb Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Treating Chronic Myeloid Leukemia by Phase Introduction
11.3.4 Pfizer Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
11.3.5 Pfizer Recent Development
11.4 Hansoh Pharmaceutical
11.4.1 Hansoh Pharmaceutical Company Details
11.4.2 Hansoh Pharmaceutical Business Overview
11.4.3 Hansoh Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Introduction
11.4.4 Hansoh Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
11.4.5 Hansoh Pharmaceutical Recent Development
11.5 Takeda Pharmaceuticals
11.5.1 Takeda Pharmaceuticals Company Details
11.5.2 Takeda Pharmaceuticals Business Overview
11.5.3 Takeda Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Introduction
11.5.4 Takeda Pharmaceuticals Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
11.5.5 Takeda Pharmaceuticals Recent Development
11.6 Sun Pharmaceuticals
11.6.1 Sun Pharmaceuticals Company Details
11.6.2 Sun Pharmaceuticals Business Overview
11.6.3 Sun Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Introduction
11.6.4 Sun Pharmaceuticals Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
11.6.5 Sun Pharmaceuticals Recent Development
11.7 Mylan
11.7.1 Mylan Company Details
11.7.2 Mylan Business Overview
11.7.3 Mylan Treating Chronic Myeloid Leukemia by Phase Introduction
11.7.4 Mylan Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
11.7.5 Mylan Recent Development
11.8 Dr. Reddy's Laboratories
11.8.1 Dr. Reddy's Laboratories Company Details
11.8.2 Dr. Reddy's Laboratories Business Overview
11.8.3 Dr. Reddy's Laboratories Treating Chronic Myeloid Leukemia by Phase Introduction
11.8.4 Dr. Reddy's Laboratories Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
11.8.5 Dr. Reddy's Laboratories Recent Development
11.9 Teva
11.9.1 Teva Company Details
11.9.2 Teva Business Overview
11.9.3 Teva Treating Chronic Myeloid Leukemia by Phase Introduction
11.9.4 Teva Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
11.9.5 Teva Recent Development
11.10 Eugia Pharma
11.10.1 Eugia Pharma Company Details
11.10.2 Eugia Pharma Business Overview
11.10.3 Eugia Pharma Treating Chronic Myeloid Leukemia by Phase Introduction
11.10.4 Eugia Pharma Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
11.10.5 Eugia Pharma Recent Development
11.11 Hetero
11.11.1 Hetero Company Details
11.11.2 Hetero Business Overview
11.11.3 Hetero Treating Chronic Myeloid Leukemia by Phase Introduction
11.11.4 Hetero Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
11.11.5 Hetero Recent Development
11.12 Sawai Pharmaceutical
11.12.1 Sawai Pharmaceutical Company Details
11.12.2 Sawai Pharmaceutical Business Overview
11.12.3 Sawai Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Introduction
11.12.4 Sawai Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
11.12.5 Sawai Pharmaceutical Recent Development
11.13 Lupin
11.13.1 Lupin Company Details
11.13.2 Lupin Business Overview
11.13.3 Lupin Treating Chronic Myeloid Leukemia by Phase Introduction
11.13.4 Lupin Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
11.13.5 Lupin Recent Development
11.14 Apotex
11.14.1 Apotex Company Details
11.14.2 Apotex Business Overview
11.14.3 Apotex Treating Chronic Myeloid Leukemia by Phase Introduction
11.14.4 Apotex Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
11.14.5 Apotex Recent Development
11.15 Chia Tai Tianqing Pharmaceutical
11.15.1 Chia Tai Tianqing Pharmaceutical Company Details
11.15.2 Chia Tai Tianqing Pharmaceutical Business Overview
11.15.3 Chia Tai Tianqing Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Introduction
11.15.4 Chia Tai Tianqing Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
11.15.5 Chia Tai Tianqing Pharmaceutical Recent Development
11.16 Qilu Pharmaceutical
11.16.1 Qilu Pharmaceutical Company Details
11.16.2 Qilu Pharmaceutical Business Overview
11.16.3 Qilu Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Introduction
11.16.4 Qilu Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
11.16.5 Qilu Pharmaceutical Recent Development
11.17 CSPC Ouyi Pharmaceutical
11.17.1 CSPC Ouyi Pharmaceutical Company Details
11.17.2 CSPC Ouyi Pharmaceutical Business Overview
11.17.3 CSPC Ouyi Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Introduction
11.17.4 CSPC Ouyi Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
11.17.5 CSPC Ouyi Pharmaceutical Recent Development
11.18 Suzhou Thery Pharmaceutical
11.18.1 Suzhou Thery Pharmaceutical Company Details
11.18.2 Suzhou Thery Pharmaceutical Business Overview
11.18.3 Suzhou Thery Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Introduction
11.18.4 Suzhou Thery Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
11.18.5 Suzhou Thery Pharmaceutical Recent Development
11.19 Lunan Pharmaceutical
11.19.1 Lunan Pharmaceutical Company Details
11.19.2 Lunan Pharmaceutical Business Overview
11.19.3 Lunan Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Introduction
11.19.4 Lunan Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
11.19.5 Lunan Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Novartis
Bristol–Myers Squibb
Pfizer Inc
Hansoh Pharmaceutical
Takeda Pharmaceuticals
Sun Pharmaceuticals
Mylan NV
Dr. Reddy’s Laboratories
TEVA
Eugia Pharma
Hetero
Sawai Pharmaceutical
Lupin Ltd
Apotex
Chia Tai-Tianqing Pharmaceutical
Qilu Pharmaceutical
CSPC Ouyi Pharmaceutical
Suzhou Thery Pharmaceutical
Lunan Pharmaceutical
List of Tables
 Table 1. Global Treating Chronic Myeloid Leukemia by Phase Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
 Table 2. Key Players of Chronic Phase
 Table 3. Key Players of Accelerated Phase
 Table 4. Key Players of Blast Phase
 Table 5. Global Treating Chronic Myeloid Leukemia by Phase Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
 Table 6. Global Treating Chronic Myeloid Leukemia by Phase Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 7. Global Treating Chronic Myeloid Leukemia by Phase Market Size by Region (2019-2024) & (US$ Million)
 Table 8. Global Treating Chronic Myeloid Leukemia by Phase Market Share by Region (2019-2024)
 Table 9. Global Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Region (2025-2030) & (US$ Million)
 Table 10. Global Treating Chronic Myeloid Leukemia by Phase Market Share by Region (2025-2030)
 Table 11. Treating Chronic Myeloid Leukemia by Phase Market Trends
 Table 12. Treating Chronic Myeloid Leukemia by Phase Market Drivers
 Table 13. Treating Chronic Myeloid Leukemia by Phase Market Challenges
 Table 14. Treating Chronic Myeloid Leukemia by Phase Market Restraints
 Table 15. Global Treating Chronic Myeloid Leukemia by Phase Revenue by Players (2019-2024) & (US$ Million)
 Table 16. Global Treating Chronic Myeloid Leukemia by Phase Market Share by Players (2019-2024)
 Table 17. Global Top Treating Chronic Myeloid Leukemia by Phase Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Treating Chronic Myeloid Leukemia by Phase as of 2023)
 Table 18. Ranking of Global Top Treating Chronic Myeloid Leukemia by Phase Companies by Revenue (US$ Million) in 2023
 Table 19. Global 5 Largest Players Market Share by Treating Chronic Myeloid Leukemia by Phase Revenue (CR5 and HHI) & (2019-2024)
 Table 20. Global Key Players of Treating Chronic Myeloid Leukemia by Phase, Headquarters and Area Served
 Table 21. Global Key Players of Treating Chronic Myeloid Leukemia by Phase, Product and Application
 Table 22. Global Key Players of Treating Chronic Myeloid Leukemia by Phase, Date of Enter into This Industry
 Table 23. Mergers & Acquisitions, Expansion Plans
 Table 24. Global Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2019-2024) & (US$ Million)
 Table 25. Global Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Type (2019-2024)
 Table 26. Global Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Type (2025-2030) & (US$ Million)
 Table 27. Global Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Type (2025-2030)
 Table 28. Global Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2019-2024) & (US$ Million)
 Table 29. Global Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Application (2019-2024)
 Table 30. Global Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Application (2025-2030) & (US$ Million)
 Table 31. Global Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Application (2025-2030)
 Table 32. North America Treating Chronic Myeloid Leukemia by Phase Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 33. North America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2019-2024) & (US$ Million)
 Table 34. North America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2025-2030) & (US$ Million)
 Table 35. Europe Treating Chronic Myeloid Leukemia by Phase Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 36. Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2019-2024) & (US$ Million)
 Table 37. Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2025-2030) & (US$ Million)
 Table 38. Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 39. Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size by Region (2019-2024) & (US$ Million)
 Table 40. Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size by Region (2025-2030) & (US$ Million)
 Table 41. Latin America Treating Chronic Myeloid Leukemia by Phase Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 42. Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2019-2024) & (US$ Million)
 Table 43. Latin America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2025-2030) & (US$ Million)
 Table 44. Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
 Table 45. Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2019-2024) & (US$ Million)
 Table 46. Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2025-2030) & (US$ Million)
 Table 47. Novartis Company Details
 Table 48. Novartis Business Overview
 Table 49. Novartis Treating Chronic Myeloid Leukemia by Phase Product
 Table 50. Novartis Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)
 Table 51. Novartis Recent Development
 Table 52. Bristol Myers Squibb Company Details
 Table 53. Bristol Myers Squibb Business Overview
 Table 54. Bristol Myers Squibb Treating Chronic Myeloid Leukemia by Phase Product
 Table 55. Bristol Myers Squibb Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)
 Table 56. Bristol Myers Squibb Recent Development
 Table 57. Pfizer Company Details
 Table 58. Pfizer Business Overview
 Table 59. Pfizer Treating Chronic Myeloid Leukemia by Phase Product
 Table 60. Pfizer Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)
 Table 61. Pfizer Recent Development
 Table 62. Hansoh Pharmaceutical Company Details
 Table 63. Hansoh Pharmaceutical Business Overview
 Table 64. Hansoh Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product
 Table 65. Hansoh Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)
 Table 66. Hansoh Pharmaceutical Recent Development
 Table 67. Takeda Pharmaceuticals Company Details
 Table 68. Takeda Pharmaceuticals Business Overview
 Table 69. Takeda Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Product
 Table 70. Takeda Pharmaceuticals Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)
 Table 71. Takeda Pharmaceuticals Recent Development
 Table 72. Sun Pharmaceuticals Company Details
 Table 73. Sun Pharmaceuticals Business Overview
 Table 74. Sun Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Product
 Table 75. Sun Pharmaceuticals Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)
 Table 76. Sun Pharmaceuticals Recent Development
 Table 77. Mylan Company Details
 Table 78. Mylan Business Overview
 Table 79. Mylan Treating Chronic Myeloid Leukemia by Phase Product
 Table 80. Mylan Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)
 Table 81. Mylan Recent Development
 Table 82. Dr. Reddy's Laboratories Company Details
 Table 83. Dr. Reddy's Laboratories Business Overview
 Table 84. Dr. Reddy's Laboratories Treating Chronic Myeloid Leukemia by Phase Product
 Table 85. Dr. Reddy's Laboratories Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)
 Table 86. Dr. Reddy's Laboratories Recent Development
 Table 87. Teva Company Details
 Table 88. Teva Business Overview
 Table 89. Teva Treating Chronic Myeloid Leukemia by Phase Product
 Table 90. Teva Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)
 Table 91. Teva Recent Development
 Table 92. Eugia Pharma Company Details
 Table 93. Eugia Pharma Business Overview
 Table 94. Eugia Pharma Treating Chronic Myeloid Leukemia by Phase Product
 Table 95. Eugia Pharma Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)
 Table 96. Eugia Pharma Recent Development
 Table 97. Hetero Company Details
 Table 98. Hetero Business Overview
 Table 99. Hetero Treating Chronic Myeloid Leukemia by Phase Product
 Table 100. Hetero Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)
 Table 101. Hetero Recent Development
 Table 102. Sawai Pharmaceutical Company Details
 Table 103. Sawai Pharmaceutical Business Overview
 Table 104. Sawai Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product
 Table 105. Sawai Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)
 Table 106. Sawai Pharmaceutical Recent Development
 Table 107. Lupin Company Details
 Table 108. Lupin Business Overview
 Table 109. Lupin Treating Chronic Myeloid Leukemia by Phase Product
 Table 110. Lupin Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)
 Table 111. Lupin Recent Development
 Table 112. Apotex Company Details
 Table 113. Apotex Business Overview
 Table 114. Apotex Treating Chronic Myeloid Leukemia by Phase Product
 Table 115. Apotex Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)
 Table 116. Apotex Recent Development
 Table 117. Chia Tai Tianqing Pharmaceutical Company Details
 Table 118. Chia Tai Tianqing Pharmaceutical Business Overview
 Table 119. Chia Tai Tianqing Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product
 Table 120. Chia Tai Tianqing Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)
 Table 121. Chia Tai Tianqing Pharmaceutical Recent Development
 Table 122. Qilu Pharmaceutical Company Details
 Table 123. Qilu Pharmaceutical Business Overview
 Table 124. Qilu Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product
 Table 125. Qilu Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)
 Table 126. Qilu Pharmaceutical Recent Development
 Table 127. CSPC Ouyi Pharmaceutical Company Details
 Table 128. CSPC Ouyi Pharmaceutical Business Overview
 Table 129. CSPC Ouyi Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product
 Table 130. CSPC Ouyi Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)
 Table 131. CSPC Ouyi Pharmaceutical Recent Development
 Table 132. Suzhou Thery Pharmaceutical Company Details
 Table 133. Suzhou Thery Pharmaceutical Business Overview
 Table 134. Suzhou Thery Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product
 Table 135. Suzhou Thery Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)
 Table 136. Suzhou Thery Pharmaceutical Recent Development
 Table 137. Lunan Pharmaceutical Company Details
 Table 138. Lunan Pharmaceutical Business Overview
 Table 139. Lunan Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product
 Table 140. Lunan Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024) & (US$ Million)
 Table 141. Lunan Pharmaceutical Recent Development
 Table 142. Research Programs/Design for This Report
 Table 143. Key Data Information from Secondary Sources
 Table 144. Key Data Information from Primary Sources
 Table 145. Authors List of This Report


List of Figures
 Figure 1. Treating Chronic Myeloid Leukemia by Phase Picture
 Figure 2. Global Treating Chronic Myeloid Leukemia by Phase Market Size Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Treating Chronic Myeloid Leukemia by Phase Market Share by Type: 2023 VS 2030
 Figure 4. Chronic Phase Features
 Figure 5. Accelerated Phase Features
 Figure 6. Blast Phase Features
 Figure 7. Global Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2024-2030) & (US$ Million)
 Figure 8. Global Treating Chronic Myeloid Leukemia by Phase Market Share by Application: 2023 VS 2030
 Figure 9. Hospitals Case Studies
 Figure 10. Clinics Case Studies
 Figure 11. Others Case Studies
 Figure 12. Treating Chronic Myeloid Leukemia by Phase Report Years Considered
 Figure 13. Global Treating Chronic Myeloid Leukemia by Phase Market Size (US$ Million), Year-over-Year: 2019-2030
 Figure 14. Global Treating Chronic Myeloid Leukemia by Phase Market Size, (US$ Million), 2019 VS 2023 VS 2030
 Figure 15. Global Treating Chronic Myeloid Leukemia by Phase Market Share by Region: 2023 VS 2030
 Figure 16. Global Treating Chronic Myeloid Leukemia by Phase Market Share by Players in 2023
 Figure 17. Global Top Treating Chronic Myeloid Leukemia by Phase Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Treating Chronic Myeloid Leukemia by Phase as of 2023)
 Figure 18. The Top 10 and 5 Players Market Share by Treating Chronic Myeloid Leukemia by Phase Revenue in 2023
 Figure 19. North America Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 20. North America Treating Chronic Myeloid Leukemia by Phase Market Share by Country (2019-2030)
 Figure 21. United States Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 22. Canada Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 23. Europe Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 24. Europe Treating Chronic Myeloid Leukemia by Phase Market Share by Country (2019-2030)
 Figure 25. Germany Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 26. France Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 27. U.K. Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 28. Italy Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 29. Russia Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 30. Nordic Countries Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 31. Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 32. Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Share by Region (2019-2030)
 Figure 33. China Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 34. Japan Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 35. South Korea Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 36. Southeast Asia Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 37. India Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 38. Australia Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 39. Latin America Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 40. Latin America Treating Chronic Myeloid Leukemia by Phase Market Share by Country (2019-2030)
 Figure 41. Mexico Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 42. Brazil Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 43. Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 44. Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Share by Country (2019-2030)
 Figure 45. Turkey Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 46. Saudi Arabia Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 47. UAE Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2019-2030) & (US$ Million)
 Figure 48. Novartis Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
 Figure 49. Bristol Myers Squibb Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
 Figure 50. Pfizer Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
 Figure 51. Hansoh Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
 Figure 52. Takeda Pharmaceuticals Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
 Figure 53. Sun Pharmaceuticals Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
 Figure 54. Mylan Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
 Figure 55. Dr. Reddy's Laboratories Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
 Figure 56. Teva Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
 Figure 57. Eugia Pharma Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
 Figure 58. Hetero Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
 Figure 59. Sawai Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
 Figure 60. Lupin Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
 Figure 61. Apotex Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
 Figure 62. Chia Tai Tianqing Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
 Figure 63. Qilu Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
 Figure 64. CSPC Ouyi Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
 Figure 65. Suzhou Thery Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
 Figure 66. Lunan Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2019-2024)
 Figure 67. Bottom-up and Top-down Approaches for This Report
 Figure 68. Data Triangulation
 Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Global Treatment for Accelerated Phase CML Market Research Report 2024
Global Treatment of Blastic Phase CML Market Research Report 2024
Global TKI for Chronic Myeloid Leukemia Market Research Report 2024
Global Chronic Myeloid Leukemia Treatment Drugs Market Research Report 2025
Global Chronic Myeloid Leukemia CML Treatment Market Insights Forecast to 2030
Global Leukemia Targeted Therapy Drugs Market Research Report 2024
Global Targeted Therapy Drugs for Leukemia Market Research Report 2024
Global Dasatinib API Market Research Report 2024
Global Targeted Drug for Leukemia Market Research Report 2024
Global Targeted Drug for Blood Cancers Market Research Report 2024
Imatinib Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global MET TKIs Market Research Report 2024
Global Ponatinib Tablets Market Research Report 2024
Nilotinib Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global EGFR TKI for Advanced NSCLC Market Research Report 2024
Global TKIs for Breast Cancer Market Research Report 2024
Global Ponatinib HCl Market Research Report 2024
Ponatinib Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Ponatinib Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Chronic Lymphocytic Leukemia CLL Treatment Market Insights Forecast to 2030

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-5L19798
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-28I6901
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22R9736
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-29A2598
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions